169 related articles for article (PubMed ID: 27491482)
1. A method for optimizing dosage regimens in oncology by visualizing the safety and efficacy response surface: analysis of inotuzumab ozogamicin.
Luu KT; Boni J
Cancer Chemother Pharmacol; 2016 Oct; 78(4):697-708. PubMed ID: 27491482
[TBL] [Abstract][Full Text] [Related]
2. Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab.
Fayad L; Offner F; Smith MR; Verhoef G; Johnson P; Kaufman JL; Rohatiner A; Advani A; Foran J; Hess G; Coiffier B; Czuczman M; Giné E; Durrant S; Kneissl M; Luu KT; Hua SY; Boni J; Vandendries E; Dang NH
J Clin Oncol; 2013 Feb; 31(5):573-83. PubMed ID: 23295790
[TBL] [Abstract][Full Text] [Related]
3. A phase 2 study of inotuzumab ozogamicin in patients with indolent B-cell non-Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy.
Goy A; Forero A; Wagner-Johnston N; Christopher Ehmann W; Tsai M; Hatake K; Ananthakrishnan R; Volkert A; Vandendries E; Ogura M
Br J Haematol; 2016 Aug; 174(4):571-81. PubMed ID: 27101934
[TBL] [Abstract][Full Text] [Related]
4. Preclinical to Clinical Translation of Antibody-Drug Conjugates Using PK/PD Modeling: a Retrospective Analysis of Inotuzumab Ozogamicin.
Betts AM; Haddish-Berhane N; Tolsma J; Jasper P; King LE; Sun Y; Chakrapani S; Shor B; Boni J; Johnson TR
AAPS J; 2016 Sep; 18(5):1101-1116. PubMed ID: 27198897
[TBL] [Abstract][Full Text] [Related]
5. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study.
Advani A; Coiffier B; Czuczman MS; Dreyling M; Foran J; Gine E; Gisselbrecht C; Ketterer N; Nasta S; Rohatiner A; Schmidt-Wolf IG; Schuler M; Sierra J; Smith MR; Verhoef G; Winter JN; Boni J; Vandendries E; Shapiro M; Fayad L
J Clin Oncol; 2010 Apr; 28(12):2085-93. PubMed ID: 20308665
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of anti-CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed/refractory B-cell non-Hodgkin lymphoma.
Ogura M; Hatake K; Ando K; Tobinai K; Tokushige K; Ono C; Ishibashi T; Vandendries E
Cancer Sci; 2012 May; 103(5):933-8. PubMed ID: 22335424
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics of inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma.
Garrett M; Ruiz-Garcia A; Parivar K; Hee B; Boni J
J Pharmacokinet Pharmacodyn; 2019 Jun; 46(3):211-222. PubMed ID: 30859374
[TBL] [Abstract][Full Text] [Related]
8. Inotuzumab ozogamicin for the treatment of patients with acute lymphocytic leukemia.
Choudhry A; O'Brien SM
Drugs Today (Barc); 2017 Dec; 53(12):653-665. PubMed ID: 29517084
[TBL] [Abstract][Full Text] [Related]
9. Rationale for optimal obinutuzumab/GA101 dosing regimen in B-cell non-Hodgkin lymphoma.
Cartron G; Hourcade-Potelleret F; Morschhauser F; Salles G; Wenger M; Truppel-Hartmann A; Carlile DJ
Haematologica; 2016 Feb; 101(2):226-34. PubMed ID: 26659915
[TBL] [Abstract][Full Text] [Related]
10. Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin.
Ricart AD
Clin Cancer Res; 2011 Oct; 17(20):6417-27. PubMed ID: 22003069
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Inotuzumab Ozogamicin (CMC-544) for the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma: A Systematic Review and Meta-Analysis.
Li X; Zhou M; Qi J; Han Y
Clin Lymphoma Myeloma Leuk; 2021 Mar; 21(3):e227-e247. PubMed ID: 33461955
[TBL] [Abstract][Full Text] [Related]
12. Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma.
Leonard JP; Coleman M; Ketas JC; Chadburn A; Ely S; Furman RR; Wegener WA; Hansen HJ; Ziccardi H; Eschenberg M; Gayko U; Cesano A; Goldenberg DM
J Clin Oncol; 2003 Aug; 21(16):3051-9. PubMed ID: 12837807
[TBL] [Abstract][Full Text] [Related]
13. Model-based simulation to support the extended dosing regimens of atezolizumab.
Chou CH; Hsu LF
Eur J Clin Pharmacol; 2021 Jan; 77(1):87-93. PubMed ID: 32808071
[TBL] [Abstract][Full Text] [Related]
14. Monoclonal antibodies for the treatment of hematologic malignancies: clinical trials in Japan.
Tobinai K
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S90-6. PubMed ID: 12819934
[TBL] [Abstract][Full Text] [Related]
15. Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study.
Sehn LH; Goy A; Offner FC; Martinelli G; Caballero MD; Gadeberg O; Baetz T; Zelenetz AD; Gaidano G; Fayad LE; Buckstein R; Friedberg JW; Crump M; Jaksic B; Zinzani PL; Padmanabhan Iyer S; Sahin D; Chai A; Fingerle-Rowson G; Press OW
J Clin Oncol; 2015 Oct; 33(30):3467-74. PubMed ID: 26282650
[TBL] [Abstract][Full Text] [Related]
16. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma.
Witzig TE; Wiernik PH; Moore T; Reeder C; Cole C; Justice G; Kaplan H; Voralia M; Pietronigro D; Takeshita K; Ervin-Haynes A; Zeldis JB; Vose JM
J Clin Oncol; 2009 Nov; 27(32):5404-9. PubMed ID: 19805688
[TBL] [Abstract][Full Text] [Related]
17. Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies.
Shor B; Gerber HP; Sapra P
Mol Immunol; 2015 Oct; 67(2 Pt A):107-16. PubMed ID: 25304309
[TBL] [Abstract][Full Text] [Related]
18. Dosage Optimization of Nemolizumab Using Population Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Modeling and Simulation.
Saito T; Iida S; Terao K; Kumagai Y
J Clin Pharmacol; 2017 Dec; 57(12):1564-1572. PubMed ID: 28703903
[TBL] [Abstract][Full Text] [Related]
19. Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting.
Morrissey KM; Marchand M; Patel H; Zhang R; Wu B; Phyllis Chan H; Mecke A; Girish S; Jin JY; Winter HR; Bruno R
Cancer Chemother Pharmacol; 2019 Dec; 84(6):1257-1267. PubMed ID: 31542806
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic profile and first preliminary clinical evaluation of bendamustine in Taiwanese patients with heavily pretreated indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.
Hsiao LT; Tien HF; Kuo CY; Wu JH; Hou HA; Wang MC; Liu CY; Chen PM; Chiou TJ
Hematol Oncol; 2015 Dec; 33(4):136-44. PubMed ID: 25111959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]